Vaxart, Inc. Announces 2024 Annual Meeting of Stockholders

TL;DR

<b>Vaxart, Inc. is holding its 2024 Annual Meeting of Stockholders on June 11, 2024, to vote on key corporate actions including director elections and stock plan amendments.</b>

AI Summary

Vaxart, Inc. (VXRT) filed a Proxy Statement (DEF 14A) with the SEC on April 29, 2024. Vaxart, Inc. will hold its 2024 Annual Meeting of Stockholders on June 11, 2024, in a virtual-only format. The meeting agenda includes the election of six director nominees, an amendment to increase authorized common stock to 350,000,000 shares, and amendments to equity incentive and employee stock purchase plans. Shareholders will vote on increasing the 2019 Equity Incentive Plan shares by 15,000,000 to 43,900,000. The 2022 Employee Stock Purchase Plan will seek an increase of 1,800,000 shares to 3,600,000. The company will also seek ratification of WithumSmith+Brown, PC as its independent registered public accounting firm for the year ending December 31, 2024.

Why It Matters

For investors and stakeholders tracking Vaxart, Inc., this filing contains several important signals. The proposed increase in authorized shares and equity incentive plan shares could facilitate future fundraising and employee compensation, impacting dilution and shareholder value. The ratification of the independent auditor is a standard governance procedure, but any changes could signal concerns about financial reporting or internal controls.

Risk Assessment

Risk Level: low — Vaxart, Inc. shows low risk based on this filing. The filing is a routine proxy statement for an annual meeting and does not contain significant new financial or operational information, indicating low immediate risk.

Analyst Insight

Stockholders should review the proposals regarding share increases and equity plans to understand potential dilution and future compensation strategies.

Key Numbers

• 2024-06-11 — Annual Meeting Date (Date of the 2024 Annual Meeting of Stockholders)
• 350,000,000 — Authorized Shares (Proposed increase in authorized common stock)
• 15,000,000 — Equity Incentive Plan Share Increase (Additional shares to be reserved under the 2019 Equity Incentive Plan)
• 43,900,000 — Total Equity Incentive Shares (Total shares reserved under the amended 2019 Equity Incentive Plan)
• 1,800,000 — ESPP Share Increase (Additional shares to be reserved under the 2022 Employee Stock Purchase Plan)
• 3,600,000 — Total ESPP Shares (Total shares reserved under the amended 2022 Employee Stock Purchase Plan)
• 2024-12-31 — Fiscal Year End (Fiscal year for which the auditor is being ratified)

Key Players & Entities

• Vaxart, Inc. (company) — Registrant name
• June 11, 2024 (date) — Date of Annual Meeting
• 350,000,000 (dollar_amount) — Proposed increase in authorized common stock
• 15,000,000 (dollar_amount) — Increase in shares for 2019 Equity Incentive Plan
• 43,900,000 (dollar_amount) — Total shares reserved under 2019 Equity Incentive Plan
• 1,800,000 (dollar_amount) — Increase in shares for 2022 Employee Stock Purchase Plan
• 3,600,000 (dollar_amount) — Total shares reserved under 2022 Employee Stock Purchase Plan
• WithumSmith+Brown, PC (company) — Independent registered public accounting firm

FAQ

Risk Factors

• Increase in Authorized Shares [medium — financial]: The proposal to increase authorized common stock could lead to future dilution if new shares are issued.
• Equity Incentive and ESPP Amendments [medium — financial]: Increasing shares reserved for equity plans may result in significant stock-based compensation, potentially diluting existing shareholders.

Key Financial Figures

• $8,500 — and informational support for a fee of $8,500 plus out-of-pocket expenses and customa

Filing Documents

• vxrt20240423_def14a.htm (DEF 14A) — 1115KB
• capni.jpg (GRAPHIC) — 26KB
• captsr.jpg (GRAPHIC) — 28KB
• proxy_page1.jpg (GRAPHIC) — 191KB
• proxy_page2.jpg (GRAPHIC) — 136KB
• 0001437749-24-013723.txt (&nbsp;) — 1642KB

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 45 DIRECTOR COMPENSATION 58

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 60 DELINQUENT SECTION 16( a ) REPORTS 61 TRANSACTIONS WITH RELATED PARTIES 62 HOUSEHOLDING OF PROXY MATERIALS 63 FORM 10-K INFORMATION; OTHER SEC FILINGS 63 OTHER MATTERS 63 i Table of Contents EXHIBITS : Exhibit A: Certificate of Amendment to Certificate of Incorporation A-1 Exhibit B: 2019 Equity Incentive Plan, as Amended B-1 Exhibit C: 2022 Employee Stock Purchase Plan, as Amended C-1 ii Table of Contents VAXART, INC. 170 Harbor Way, Suite 300 South San Francisco, California 94080 PROXY STATEMENT FOR THE 2024 ANNUAL MEETING OF STOCKHOLDERS June 11, 2024 QUESTIONS AND ANSWERS ABOUT THESE PROXY MATERIALS AND VOTING Who is Vaxart? We are a clinical-stage biotechnology company primarily focused on the development of oral recombinant vaccines based on our Vector-Adjuvant-Antigen Standardized Technology (" VAAST ") proprietary oral vaccine platform. Our oral vaccines are designed to generate broad and durable immune responses that may protect against a wide range of infectious diseases and may be useful for the treatment of chronic viral infections and cancer. Our investigational vaccines are administered using a room temperature-stable tablet, rather than by injection. We are developing prophylactic vaccine candidates that target a range of infectious diseases, including norovirus (a widespread cause of acute gastroenteritis), coronavirus, including SARS-CoV-2 (the virus that causes coronavirus disease 2019 (" COVID-19 ")), and influenza. We believe our oral tablet vaccine candidates offer important advantages: First, they are designed to generate broad and durable immune responses, including systemic, mucosal and T cell responses, which may enhance protection against certain infectious diseases, such as norovirus, COVID-19 and influenza, and may have potential clinical benefit for certain cancers and chronic viral infections, such as those ca

View Full Filing

View this DEF 14A filing on SEC EDGAR